Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.35
NAS:CTIC's Cash to Debt is ranked lower than
67% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:CTIC: 3.35 )
Ranked among companies with meaningful Cash to Debt only.
NAS:CTIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.28 Max: No Debt
Current: 3.35
Equity to Asset 0.43
NAS:CTIC's Equity to Asset is ranked lower than
76% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CTIC: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CTIC' s Equity to Asset Range Over the Past 10 Years
Min: -2.7  Med: 0.04 Max: 0.95
Current: 0.43
-2.7
0.95
F-Score: 3
Z-Score: -30.46
M-Score: -1.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -130.24
NAS:CTIC's Operating margin (%) is ranked lower than
55% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:CTIC: -130.24 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CTIC' s Operating margin (%) Range Over the Past 10 Years
Min: -123250  Med: -12650.83 Max: -119.75
Current: -130.24
-123250
-119.75
Net-margin (%) -133.07
NAS:CTIC's Net-margin (%) is ranked lower than
56% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:CTIC: -133.07 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CTIC' s Net-margin (%) Range Over the Past 10 Years
Min: -169773.75  Med: -13740.68 Max: -123.26
Current: -133.07
-169773.75
-123.26
ROE (%) -328.35
NAS:CTIC's ROE (%) is ranked lower than
96% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:CTIC: -328.35 )
Ranked among companies with meaningful ROE (%) only.
NAS:CTIC' s ROE (%) Range Over the Past 10 Years
Min: -1010.2  Med: -261.49 Max: -124.54
Current: -328.35
-1010.2
-124.54
ROA (%) -74.39
NAS:CTIC's ROA (%) is ranked lower than
80% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:CTIC: -74.39 )
Ranked among companies with meaningful ROA (%) only.
NAS:CTIC' s ROA (%) Range Over the Past 10 Years
Min: -261.37  Med: -120.92 Max: -51.06
Current: -74.39
-261.37
-51.06
ROC (Joel Greenblatt) (%) -1956.46
NAS:CTIC's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:CTIC: -1956.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CTIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2837.37  Med: -1865.51 Max: -527.54
Current: -1956.46
-2837.37
-527.54
EBITDA Growth (3Y)(%) -28.50
NAS:CTIC's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:CTIC: -28.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CTIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -84  Med: -29.2 Max: 26.4
Current: -28.5
-84
26.4
EPS Growth (3Y)(%) -31.00
NAS:CTIC's EPS Growth (3Y)(%) is ranked lower than
80% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:CTIC: -31.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:CTIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -82.7  Med: -26.6 Max: 24.6
Current: -31
-82.7
24.6
» NAS:CTIC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CTIC Guru Trades in Q2 2015

Jim Simons 561,124 sh (New)
Paul Tudor Jones 68,600 sh (-21.06%)
» More
Q3 2015

CTIC Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2016

CTIC Guru Trades in Q1 2016

Paul Tudor Jones 188,500 sh (New)
Jim Simons 12,200 sh (New)
» More
Q2 2016

CTIC Guru Trades in Q2 2016

Jim Simons 315,544 sh (+2486.43%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:GTXI, NAS:AVXL, NAS:VBLT, OTCPK:OXBDF, NAS:XENE, NAS:CDXC, AMEX:CRMD, NAS:AKTX, NAS:AKAO, NAS:SBBP, NAS:MRTX, NAS:ARQL, OTCPK:PHGUF, NAS:ORMP, NAS:VVUS, NAS:KIN, NAS:ONS, NAS:QLTI, NAS:EIGR, NAS:CRME » details
Traded in other countries:CEPR.Germany, CTIC.Italy, 0QUJ.UK,
CTI Biopharma Corp is a biopharmaceutical company. The Company is engaged in acquiring, developing & bringing market less toxic, more effective therapies to treat and cure cancer.

CTI Biopharma Corp was incorporated in Washington in 1991. It is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer benefit to patients and health care providers. It is currently concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, it is primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The Company is subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies.

Ratios

vs
industry
vs
history
P/B 2.64
CTIC's P/B is ranked higher than
66% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CTIC: 2.64 )
Ranked among companies with meaningful P/B only.
CTIC' s P/B Range Over the Past 10 Years
Min: 1.83  Med: 19.59 Max: 99
Current: 2.64
1.83
99
P/S 1.76
CTIC's P/S is ranked higher than
89% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CTIC: 1.76 )
Ranked among companies with meaningful P/S only.
CTIC' s P/S Range Over the Past 10 Years
Min: 0.05  Med: 85.36 Max: 7287.5
Current: 1.76
0.05
7287.5
Current Ratio 2.18
CTIC's Current Ratio is ranked lower than
74% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CTIC: 2.18 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.58 Max: 24.99
Current: 2.18
0.38
24.99
Quick Ratio 2.12
CTIC's Quick Ratio is ranked lower than
70% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CTIC: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.54 Max: 24.96
Current: 2.12
0.38
24.96
Days Inventory 555.55
CTIC's Days Inventory is ranked lower than
96% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. CTIC: 555.55 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 16.31  Med: 1080.1 Max: 8925.18
Current: 555.55
16.31
8925.18
Days Sales Outstanding 3.64
CTIC's Days Sales Outstanding is ranked higher than
94% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CTIC: 3.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47  Med: 21.79 Max: 834.94
Current: 3.64
2.47
834.94
Days Payable 2.00
CTIC's Days Payable is ranked lower than
92% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. CTIC: 2.00 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 2592.11 Max: 49126.02
Current: 2
2
49126.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.70
CTIC's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CTIC: -36.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -442.4  Med: -63.4 Max: 5.3
Current: -36.7
-442.4
5.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.57
CTIC's Price/Net Cash is ranked higher than
54% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. CTIC: 5.57 )
Ranked among companies with meaningful Price/Net Cash only.
CTIC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.7  Med: 31.51 Max: 748.07
Current: 5.57
2.7
748.07
Price/Net Current Asset Value 3.25
CTIC's Price/Net Current Asset Value is ranked higher than
74% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CTIC: 3.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CTIC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.69  Med: 19.83 Max: 329
Current: 3.25
0.69
329
Price/Tangible Book 2.64
CTIC's Price/Tangible Book is ranked higher than
73% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. CTIC: 2.64 )
Ranked among companies with meaningful Price/Tangible Book only.
CTIC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.6  Med: 17.38 Max: 81
Current: 2.64
0.6
81
Price/Median PS Value 0.02
CTIC's Price/Median PS Value is ranked higher than
99% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CTIC: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
CTIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.58 Max: 487.51
Current: 0.02
0.01
487.51
Earnings Yield (Greenblatt) (%) -142.90
CTIC's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CTIC: -142.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3151.75  Med: 0 Max: 0
Current: -142.9
-3151.75
0

More Statistics

Revenue (TTM) (Mil) $56.12
EPS (TTM) $ -0.36
Beta0.43
Short Percentage of Float0.46%
52-Week Range $0.25 - 1.75
Shares Outstanding (Mil)282.82

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.78
EPS w/o NRI ($) -0.78
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule Sep 22 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Sep 19 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 31 2016
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up Aug 30 2016
CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial Aug 29 2016
CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk... Aug 29 2016
CTI BIOPHARMA CORP Financials Aug 13 2016
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate... Aug 11 2016
CTI BioPharma reports 2Q loss Aug 04 2016
CTI BioPharma reports 2Q loss Aug 04 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2016
CTI BioPharma Reports Second Quarter 2016 Financial Results Aug 04 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jul 28 2016
ETF’s with exposure to CTI BioPharma Corp. : July 20, 2016 Jul 20 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 30 2016
ETF’s with exposure to CTI BioPharma Corp. : June 27, 2016 Jun 27 2016
Surging Earnings Estimates Signal Good News for CTI BioPharma (CTIC) Jun 10 2016
Should CTI BioPharma (CTIC) Be On Your Radar Now? Jun 08 2016
Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting Jun 07 2016
ETF’s with exposure to CTI BioPharma Corp. : June 3, 2016 Jun 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)